

## ZULRESSO - (100MG/20ML ; Solution)

|                              |   |                             |                     |
|------------------------------|---|-----------------------------|---------------------|
| <b>Generic Name</b>          | BREXANOLONE   | <b>Innovator</b>            | SAGE THERAP         |
| <b>Dosage</b>                | 100MG/20ML ; Solution   | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | None  | <b>Known Para IV Filers</b> | None                |
| <b>Other ANDA developers</b> | None  | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | None  | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | ZULRESSO is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression (PPD) in patients 15 years and older. |                             |                     |
| <b>Complexities</b>          | Yes   |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.